Anal Cancer for Gastroenterologists

Differentiate the anal canal, anorectal junction, transformation zone, and perianal skin using clinically relevant anatomic landmarks.

Distinguish anal squamous intraepithelial lesions and invasive squamous cell carcinoma by terminology, pathology, and expected disease course.

Stratify a patient’s anal cancer risk using HIV status, immune suppression, prior HPV-related disease, smoking, and other established factors.

Differentiate anal squamous cell carcinoma from adenocarcinoma, melanoma, and common benign mimics using clinical and pathology findings.

Identify patients for whom anal cancer screening should be considered under current U.S. guidance and consensus recommendations.

Select an anal cancer screening approach using symptom assessment, digital anorectal examination, anal cytology, high-risk HPV testing, and local access to high-resolution anoscopy.

Interpret anal cytology and high-risk HPV results to determine the appropriate follow-up or specialist referral.

Recommend HPV vaccination and modifiable risk-factor interventions relevant to anal cancer prevention in eligible adults.

Perform a focused evaluation for suspected anal cancer using symptom history, perianal inspection, digital anorectal examination, and inguinal node assessment.

Conduct and document a systematic anal and rectal inspection during lower endoscopy, including appropriate use of forward and retroflexed views.

Recognize lesion features that warrant biopsy or expedited referral rather than routine management as hemorrhoidal or inflammatory disease.

Choose an appropriate biopsy or referral strategy based on lesion location, suspected invasion, procedural risk, and access to high-resolution anoscopy or colorectal surgery.

Interpret an anal lesion pathology report for grade, invasion, histologic subtype, and clinically important ancillary findings.

Assign the clinical TNM category of anal squamous cell carcinoma from tumor size, adjacent-organ involvement, and regional nodal findings.

Select NCCN-aligned imaging and clinical studies for the initial staging of confirmed anal squamous cell carcinoma.

Construct an efficient multidisciplinary referral plan involving colorectal surgery, medical oncology, radiation oncology, radiology, pathology, and HIV care when applicable.

Determine when local excision is appropriate for a carefully selected superficial anal margin or anal canal lesion.

Explain the components and treatment intent of definitive chemoradiation for localized anal squamous cell carcinoma.

Recognize acute gastrointestinal, dermatologic, hematologic, and infectious complications of anal cancer chemoradiation that require supportive care or urgent escalation.

Differentiate management pathways for persistent, recurrent, and metastatic anal squamous cell carcinoma, including indications for salvage surgery and systemic therapy.

Assess clinical response after chemoradiation while accounting for the expected time course of continued tumor regression.

Build an NCCN-aligned surveillance plan using digital rectal examination, inguinal node examination, anoscopy, and indicated imaging.

Evaluate post-treatment anorectal symptoms for recurrence, radiation injury, infection, stenosis, fistula, and benign gastrointestinal causes.

Formulate initial gastroenterology management and referral plans for chronic radiation proctopathy, bowel dysfunction, pain, and other survivorship concerns.